Drug intelligence / Profile preview

lactobacillus plantarum 299v + sertraline

Development stage: Phase 2
Modality: Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration: Oral

Overview

This is a combination therapy consisting of the probiotic bacterium Lactobacillus plantarum 299v and the selective serotonin reuptake inhibitor (SSRI) sertraline. Lactobacillus plantarum 299v is a probiotic strain that modulates gut microbiota and has been shown to influence tryptophan metabolism, particularly by decreasing kynurenine concentrations, which may contribute to improved cognitive function in patients with major depressive disorder (MDD). Sertraline is an SSRI antidepressant that increases synaptic serotonin levels by inhibiting its reuptake in the brain, thereby alleviating symptoms of depression. Clinical studies have demonstrated that augmentation of SSRI treatment with Lactobacillus plantarum 299v can improve cognitive performance and reduce kynurenine concentration in MDD patients compared to placebo[2][5][6]. The combination targets both central nervous system neurotransmission (via sertraline) and gut-brain axis modulation (via L. plantarum 299v).

Targets

SERT (Sodium-dependent serotonin transporter)KMO (Kynurenine 3-monooxygenase)

Beyond the preview

Go deeper on lactobacillus plantarum 299v + sertraline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus plantarum 299v + sertraline.